31
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Neutrophil Apoptosis in Patients with β-Thalassemia Major

, , , , , , , & show all
Pages 237-243 | Published online: 09 Jul 2009

  • Weatherall DJ, CleggJB. The Tialassemia Syndromes, ed 2. Oxford, UK: Blackwell Scientific; 1981.
  • WHO. Community control of hereditary anemias: memorandum from a WHO meeting. Bull WHO. 1983;61:63.
  • Baysal E, Carver MF. The beta-and delta-thalassemia repository, ed 8. Hemoglobin. 1995; 19:213-216.
  • Aksoy M, Kudar A, Kudar F, Dincol G, Erdem S, BastesbihU+00E7i S. Survey on hemoglobin variants, beta thalassemia, glucose-6-phosphate dehydrogenase deficiency, and haptoglobin types in Turks from western thrace. J Med Genet. 1985;22:288-290.
  • Fessas P. Inclusions of hemoglobin in erytroblasts and erythrocytes of thalassemia. Blood. 1963;21:21.
  • Bargellesi A, Pontremoli S, Menini C, Conconi F. Excess of alpha globin synthesis in homozygous beta-thalassemia and its removal from the red blood cell cytoplasm. Eur J Biochem. 1968;3:364-368.
  • Yuan J, Angelucci E, Lucarelli G, et al. Accelerated programmed cell death (apoptosis) in erythroid precursors of patients with severe beta-thalassemia (Cooley's anemia). Blood. 1993;82:374-377.
  • Centis F, Tabellini L, Lucarelli G, et al. The importance of erythroid expansion in determining the extent of apoptosis in erythroid precursors in patients with beta-thalassemia major. Blood. 2000;96:3624-3629.
  • Orkin SH, Nathan DG. The thalassemias. In: Orkin SH, Nathan DG, eds. Hematology of Infancy and Childhood, ed 5. Philadelphia: WB Saunders; 1998:811-816.
  • Bassaris HP, Lianou PE, Skoutelis AT, Papavassiliou JT, Phair JP. Defective adherence of polymorphonuclear leukocytes to nylon induced by thalassemic serum. J Infect Dis. 1982;146:52-55.
  • Khan AJ, Lee CK, WoIff JA, Chang H, Khan P, Evans HE. Defects of neutrophil chemotaxis and random migration in thalassemia major. Pediatrics. 1977;60:349-351.
  • Skoutelis AT, Lianou E, Papavassiliou T, Karamerou A, Politi K, Bassaris HP. Defective phagocytic and bactericidal function of polymorphonuclear leucocytes in patients with beta-thalassaemia major. J Infect. 1984;8:118-122.
  • Cantinieaux B, Hariga C, Ferster A, De Maertelaere E, Toppet M, Fondu P. Neutrophil dysfunctions in thalassaemia major the role of cell iron overload. Eur J Haematol. 1987;39:28-34.
  • Kütükçüler N, Kutlu O, Nisli G, Öztop S, Çetingul N, Çaglayan S. Assessment of neutrophil chemotaxis and random migration in children with thalassemia major. Pediatr Hematol Oncol. 1996;13:239-245.
  • Cantinieaux B, Janssens A, Boelaert JR, et al. Ferritin-associated iron induces neutrophil dysfunction in hemosiderosis. J Lab Clin Med. 1999;133:353-361.
  • Sofroniadou K, Drossou M, Foundoulaki L, Konstantopoulos K, Kyriakoy D, Zervas J. Acute bone marrow aplasia associated with intravenous administration of deferoxamine (desferrioxamine). Drug Safety. 1990;5:152-154.
  • Olivieri NF, Buncic JR,Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986;314:869-873.
  • Koren G, Bentur Y, Strong D, et al. Acute changes in renal function associated with deferoxamine therapy. Am J Dis Child 1989;143:1077-1080.
  • Olivieri NF, Koren G, Harris J, et al. Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol. 1992; 14:48-56.
  • Hoffbrand AV, Geneshaguru K, Hooton JML, Tattersall MHN. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br J Haematol. 1976;33:517-526.
  • Tomoyasu S, Nakamaki T, Suzuki K, Tsuruoka N. Growth inhibition and promotion of differentiation induction in cultured leukemia cell lines by deferoxamine. Nippon Ketsueki Gakkai Zasshi 1987;50:568-574.
  • Poison RJ, Jenkins R, Lombard M, et al. Mechanisms of inhibition of mononuclear cell activation by the iron-chelating agent desferrioxamine. Immunology. 1990;71:176-181.
  • Fukuchi K, Tomoyasu S, Isuruoka N, Gomi K. Iron deprivation-induced apoptosis in HL-60 cells. FEBS Lett. 1994;350:139-142.
  • Kyriakou D, Eliopoulos AG, Papadakis A, Alexandrakis M, Eliopoulos GD. Decreased expression of c-myc oncoprotein by peripheral blood mononuclear cells in thalassaemia patients receiving desferrioxamine. Eur J Haematol. 1998;60:21-27.
  • Boyum A. Seperation of leukocytes from blood and bone marrow. ScandJ Clin Invest Suppl. 1968;97:7.
  • Martin SJ, Reutelingsperger CP, Mc Gahon AJ, et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl J Exp Med. 1995; 182:1545-1556.
  • Naito M, Nagashima K, Mashima T, Tsuruo T. Phosphatidylserine extemalization is a downstream event of interleukin-1 beta-converting enzyme family protease activation during apoptosis. Blood. 1997;89:2060-2066.
  • Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis: flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Imrmmol Methods. 1995;184:39-51.
  • Homburg CHE, de Haas M, von dem Borne AEGK, Verhoeven AJ, Reutelingsperger CPM, Roos D. Human neutrophils lose their surface Fey RIII and acquire Annexin V binding sites during apoptosis in vitro. Blood. 1995;85:532-540.
  • Hann HW, Sthalhut MW, Lee S, London WT, Hann RS. Effects of isoferritins on human granulocytes. Cancer. 1989;63:2492-2496.
  • Cantinieaux B, Hariga C, Ferster A, Toppet M, Fondu P. Desferrioxamine improves neutrophil phagocytosis in thalassemia major. Am J Hematol. 1990;35:13-17.
  • Binet JL, Mentz F, Merle-Beral H. Apoptosis in blood diseases. Review new data. Hematol Cell Ther. 1996;38:253-264.
  • Ginis I, Faller DV. Integrin-mediated adhesion to activated endothelium protects human neutrophils from apoptosis. Blood. 1995;86(Suppl 1):501.
  • Butthep P, Bunyaratvej A, Funahara Y, et al. Possible evidence of endothelial cell activation and disturbance in thalassemia: an in vitro study. Southeast Asian J Trop Med Public Health. 1997;28 (Suppl 3):141-148.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.